Initial clinical and treatment patterns of advanced differentiated thyroid cancer : ERUDIT study
Vallejo Casas, Juan Antonio (Insituto Maimónides de Investigación Biomédica (Córdoba))
Sambo, Marcel (Hospital General Universitario Gregorio Marañón)
López-López, Carlos A (Instituto de Investigación Marqués de Valdecilla)
Durán-Poveda, Manuel (Hospital Universitario Rey Juan Carlos (Madrid))
Rodríguez-Villanueva García, Julio (EISAI Farmacéutica SA)
Santos, Rita Joana (Department of Endocrinology. Francisco Gentil Portuguese Institute of Oncology of Lisbon)
Llanos, Marta (Hospital Universitario de Canarias (La Laguna))
Navarro-González, Elena (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Aller, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Pubul, Virginia (Hospital Universitario Santiago de Compostela)
Guadalix, Sonsoles (Hospital Universitario 12 de Octubre (Madrid))
Crespo, Guillermo (Hospital Universitario de Burgos)
González, Cintia (Institut d'Investigació Biomèdica Sant Pau)
Zafón, Carles (Hospital Universitari Vall d'Hebron)
Navarro, Miguel (Hospital Universitario de Salamanca)
Santamaría-Sandi, Javier (Hospital Universitario de Cruces (Barakaldo, País Basc))
Segura, Ángel (Hospital Universitari i Politècnic La Fe (València))
Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid))
Gómez-Balaguer, Marcelino (Hospital Universitari Doctor Peset (València))
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada))
Puig-Domingo, Manel (Institut Germans Trias i Pujol)
Galofré, Juan C (Hospital Universitario de Navarra)
Castelo Fernández, Beatriz (Hospital Universitario La Paz (Madrid))
Villanueva, María José (Hospital Universitario de Vigo)
Argüelles, Iñaki (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Orcajo-Rincón, Lorenzo (EISAI Farmacéutica SA)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	Background: Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS). Objective: The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal. Methods: A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated. Results: Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10. 4 (7. 3-15. 3) years) and median disease-specific-survival (95% CI) (11. 1 (8. 7-16. 2) years; log-rank test P = 0. 4737). Age at diagnosis being 55 years was associated with a lower risk of death (Wald chi-square (Wc-s) P 0. 0001), while a poor response to RAI to a higher risk of death ((Wc-s) P 0. 05). In the eDTC cohort, median (RP)FS (95% CI) was of 1. 7 (1. 0-2. 0) years after RAI, with R0/R1 surgeries being the only common significant favourable factor for longer (RP)FS and time to aDTC ((Wc-s) P 0. 05). Conclusion: Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.
Nota:	Altres ajuts: Eisai Farmacéutica S.A. (Madrid, Spain).
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Advanced differentiated thyroid cancer ; Relapsing differentiated thyroid cancer ; Radioiodine-refractory differentiated thyroid cancer ; Epidemiological study ; Relapsing prognostic factors ; Survival prognostic factors
Publicado en:	European Thyroid Journal, Vol. 11 Núm. 5 (october 2022) , p. e210111, ISSN 2235-0802

DOI: 10.1530/ETJ-21-0111
PMID: 35900793

13 p, 2.4 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados